Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.jubilantpharmova.com | |
Market Cap | 5,364.59 Cr. | |
Enterprise Value(EV) | 7,699.44 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 10.24 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 32.66 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.78 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 343.77 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 0.97 | Calculated using Price: 334.40 |
Dividend Yield | 1.48 | Period Ending 2022-03 |
No. of Shares Subscribed | 15.93 Cr. | 159,281,139 Shares |
FaceValue | 1 | |
Company Profile | ||
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals. Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US. |
1 Day |
|
-1.09% |
1 Week |
|
-6.32% |
1 Month |
|
-10.92% |
3 Month |
|
-9.89% |
6 Month |
|
-7.57% |
1 Year |
|
-35.80% |
2 Year |
|
-62.28% |
5 Year |
|
-64.01% |
10 Year |
|
+51.62% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 5.39 | -1.58 | 14.27 | 17.95 | 16.87 | 12.97 | 13.02 | 10.88 | 8.41 | |
Return on Capital Employed (%) | 7.92 | 5.72 | 12.42 | 14.44 | 15.21 | 13.06 | 12.20 | 11.89 | 10.09 | |
Return on Assets (%) | 1.60 | -0.46 | 4.46 | 6.52 | 6.91 | 5.55 | 5.74 | 5.34 | 4.55 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 2,627 | 2,454 | 2,966 | 3,436 | 4,087 | 4,809 | 5,604 | 4,741 | 5,319 | 5,476 | |
Non Curr. Liab. | 2,185 | 4,036 | 3,347 | 3,826 | 3,417 | 4,420 | 4,088 | 2,973 | 2,922 | 3,524 | |
Curr. Liab. | 3,894 | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | 1,049 | 1,592 | 1,491 | |
Minority Int. | 158 | -38 | -47 | -52 | 0 | 0 | -2 | -4 | |||
Equity & Liab. | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,486 | |
Non Curr. Assets | 5,936 | 5,904 | 5,864 | 5,951 | 6,267 | 6,734 | 7,272 | 5,811 | 6,320 | 6,866 | |
Curr. Assets | 2,928 | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | 2,953 | 3,509 | 3,620 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,486 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 5,803 | 5,826 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 5,889 | |
Other Income | 19 | 42 | 13 | 25 | 40 | 36 | 37 | 18 | 11 | 27 | |
Total Income | 5,822 | 5,869 | 5,763 | 5,886 | 7,558 | 9,147 | 6,013 | 6,116 | 6,141 | 5,917 | |
Total Expenditure | -4,782 | -5,125 | -4,502 | -4,516 | -5,999 | -7,372 | -4,428 | -4,702 | -4,974 | -5,037 | |
PBIDT | 1,040 | 744 | 1,260 | 1,370 | 1,558 | 1,775 | 1,585 | 1,414 | 1,168 | 880 | |
Interest | -337 | -368 | -371 | -341 | -284 | -220 | -200 | -184 | -145 | -158 | |
Depreciation | -281 | -288 | -347 | -291 | -415 | -371 | -340 | -349 | -382 | -382 | |
Taxation | -70 | -80 | -155 | -163 | -225 | -327 | -335 | -297 | -217 | -120 | |
Exceptional Items | -214 | -48 | -280 | -33 | -21 | -57 | |||||
PAT | 138 | -40 | 387 | 575 | 634 | 577 | 678 | 563 | 423 | 163 | |
Minority Interest | -29 | -18 | 5 | 1 | 8 | -3 | 0 | 1 | 2 | ||
Share Associate | 11 | -10 | -1 | ||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 109 | -58 | 392 | 576 | 643 | 574 | 898 | 836 | 414 | 163 | |
Adjusted EPS | 7 | -4 | 25 | 37 | 41 | 36 | 56 | 53 | 26 | 10 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 970 | 772 | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | |
Cash Fr. Inv. | -500 | -174 | -343 | -313 | -450 | -618 | -1,012 | -327 | -739 | -380 | |
Cash Fr. Finan. | -450 | -414 | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | |
Net Change | 20 | 183 | -63 | -56 | 132 | -216 | 767 | 166 | -664 | 425 | |
Cash & Cash Eqvt | 280 | 473 | 392 | 339 | 456 | 244 | 1,005 | 1,231 | 502 | 984 |
Fri, 27 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Schedule of Investor Conference Call - Unaudited Financial Results for the quarter and nine months ended December 31 2022 |
Wed, 25 Jan 2023
Board Meeting Intimation for Consideration Of Inter-Alia Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2022 Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Consideration of inter-alia Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2022 |
Tue, 10 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 |
Mon, 30 Jan 2023 |
|
|
|
|
|